title: Four-component pharmacophore model for endomorphins toward μ opioid receptor subtypes.
abstract: In the present work, a series of simulation tools were used to determine structure-activity relationships for the endomorphins (EMs) and derive μ-pharmacophore models for these peptides. Potential lowest energy conformations were determined in vacuo by systematically varying the torsional angles of the Tyr(1)-Pro(2) (ω(1)) and Pro(2)-Trp(3)/Phe(3) (ω(2)) as tuning parameters in AM1 calculations. These initial models were then exposed to aqueous conditions via molecular dynamics simulations. In aqueous solution, the simulations suggest that endomorphin conformers strongly favor the trans/trans pair of the ω(1)/ω(2) amide bonds. From two-dimensional probability distributions of the ring-to-ring distances with respect to the pharmacophoric angles for EMs, a selectivity range of μ(1) is ca. 8.3 ~ 10.5 Å for endomorphin-2 and selectivity range of μ(2) is ca. 10.5 ~ 13.0 Å for endomorphin-1 were determined. Four-component μ-pharmacophore models are proposed for EMs and are compared to the previously published δ- and κ-pharmacophore models.
authors: Biomedical Engineering Program, Department of Engineering Science, National Cheng Kung University, Tainan 70101, Taiwan.
authors: Yng-Ching
authors: YC
authors: Wu
authors: Tim
authors: T
authors: Jaglinski
authors: Jin-Yuan
authors: JY
authors: Hsieh
authors: Jia-Jyun
authors: JJ
authors: Chiu
authors: Tzen-Yuh
authors: TY
authors: Chiang
authors: Chi-Chuan
authors: CC
authors: Hwang
references: Peptides. 1998;19(9):1603-30
references: 9864069
references: Bioorg Med Chem. 2007 May 15;15(10):3539-47
references: 17368034
references: Acta Crystallogr D Biol Crystallogr. 2004 Aug;60(Pt 8):1355-63
references: 15272157
references: Biopolymers. 2000 Jun;53(7):565-80
references: 10766952
references: Biopolymers. 2002;66(5):287-93
references: 12539257
references: Int J Pept Protein Res. 1991 May;37(5):364-81
references: 1917292
references: Bioorg Med Chem. 2007 Jun 1;15(11):3883-8
references: 17395470
references: J Pept Res. 2003 Oct;62(4):145-57
references: 12969194
references: J Phys Chem B. 2007 Jun 28;111(25):7377-83
references: 17530883
references: FEBS Lett. 1998 Nov 13;439(1-2):13-20
references: 9849868
references: FEBS J. 2005 Oct;272(19):5079-97
references: 16176278
references: Biophys J. 2000 Feb;78(2):590-9
references: 10653774
references: J Mol Biol. 1999 Aug 6;291(1):163-75
references: 10438613
references: Curr Top Med Chem. 2004;4(1):105-21
references: 14754379
references: J Pept Res. 2001 Nov;58(5):399-412
references: 11892849
references: J Pharmacol Exp Ther. 1989 Nov;251(2):461-8
references: 2553920
references: Biopolymers. 2003 Apr;68(4):497-511
references: 12666175
references: Bioorg Med Chem. 2003 May 1;11(9):1983-94
references: 12670649
references: Biochem Biophys Res Commun. 2001 Jun 15;284(3):771-6
references: 11396969
references: Trends Pharmacol Sci. 1999 Jan;20(1):19-26
references: 10101958
references: Nature. 1997 Apr 3;386(6624):499-502
references: 9087409
references: Eur J Pharmacol. 1999 May 7;372(1):25-30
references: 10374711
references: Brain Res. 2000 Oct 20;881(1):1-8
references: 11033087
references: J Med Chem. 2005 May 5;48(9):3153-63
references: 15857121
references: J Med Chem. 2004 Jan 29;47(3):735-43
references: 14736254
references: Protein Pept Lett. 2007;14(1):51-6
references: 17266651